top of page

Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence

ESCHBORN, Germany, May 30, 2022

Innoplexus, a global leader in AI-based drug discovery and development, and Inflection Biosciences Ltd., an innovative biotechnology company focused upon developing innovative small molecule therapeutics for the treatment of cancer, autoimmune and inflammatory diseases, are partnering to accelerate development of Inflection Biosciences’ preclinical stage, pan-PIM kinase inhibitor IBL-101.

The partnership aims to optimize and expedite development of IBL-101 by using Innoplexus’ Ontology and its state-of-the-art Artificial Intelligence and Machine Learning technologies to identify the most promising and targetable indications across all therapeutic areas. During this process, Innoplexus will also d

etermine combinatorial partners for IBL-101 and identify biomarkers that will foster the identification of the most suitable patients potentially benefiting the most from this therapy based on their pheno- and genotypes.

Darren Cunningham, CEO and Co-Founder of Inflection Biosciences commented: “This collaboration with leading AI company Innoplexus will build on our expertise in PIM kinase and will allow us to identify the very best application of our IBL-101 program from across many therapeutic areas. It aims to provide insights that will allow for a more effective development strategy, shortening approval lead times and cutting down upon development cost, which should ultimately benefit those patients who are in need of new treatments.”

The partnership will leverage Innoplexus’ artificial intelligence platform called Ontosight, which delves into terabytes of unstructured and structured data extracting the relevant life science information requested and required.

Innoplexus’ Life Science Language Processing™, with a self-learning Ontology of over 30 million biomedical concepts and terms, is going to be used to identify the links between the target protein, signaling pathways, mechanism of action of th

e drug and diseases. It will also provide data driven insights and recommendations for selecting indications for IBL-101 with high likelihood of success in clinical trials. Furthermore, Ontosight will also lay the groundwork for identifying optimal combinatorial therapy and identifying specific patient groups that are most likely to respond based on omic biomarkers.

Prof. Juergen Scheele, MD, PhD, SVP and CMO at Innoplexus, highlights the importance of leveraging AI-driven insights to power drug discovery and development: “Using Innoplexus’ AI and Ontology, which possesses the capabilities to collect and structure the existing world of research on kinase inhibitors, it is possible to identify the most promising avenues for further clinical research at incredible speed.”

According to the terms of the collaboration, Innoplexus will receive upfront equity in Inflection Biosciences, along with milestone payments subject to meeting specific conditions of the collaboration. Innoplexus will also be remunerated in royalties on sales of IBL-101, once results from the collaboration are utilized in its development and commercialization. No further financial details were disclosed.

About IBL-101

IBL-101 is a small molecule, orally available, pan-PIM kinase inhibitor in pre-clinical stage of development. The PIM family of serine/threonine kinases, consisting of PIM-1, PIM-2, and PIM-3, controls cell survival, proliferation, and apoptosis. In addition to being extensively studied in tumorigenesis, the role of PIM kinases has recently been revealed in inflammatory and autoimmune settings. Because the expression of PIM kinases is regulated by the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway, PIM kinases are considered a downstream effector of many cytokine signalling pathways which drive inflammation/autoimmunity. In pre-clinical models, PIM kinase inhibition downregulates the production of Th1- and Th17-type cytokines and skews T-cell differentiation towards a Treg phenotype.

About Innoplexus

Innoplexus is a leading global AI-based company for drug discovery and development with over 300 employees and 120+ patent applications including 50+ grants in artificial intelligence, machine learning and blockchain technologies. Innoplexus' solutions can generate real-time insights from hundreds of terabytes of structured and unstructured private and public data, thereby facilitating continuous, informed decision-making for its customer base at an unparalleled speed. Founded in 2015, Innoplexus AG is headquartered in Eschborn, Germany, with offices in Pune, India, and Iselin and San Francisco, United States. For more information, please visit

About Inflection Biosciences

Inflection Biosciences Ltd is developing small molecule therapeutics for the treatment of cancer, autoimmune and inflammatory diseases. IBL-101 is a pan-PIM kinase inhibitor in preclinical development as a novel clinical target for the treatment of autoimmune/inflammatory diseases. IBL-101 is also in preclinical development for the treatment of solid tumors and treatment resistance. IBL-202 is a first-in-class, dual PIM kinase and PI3K inhibitor in development for aggressive B-cell malignancies, T-cell lymphoma and acute myeloid leukemia. The partnered pipeline comprises first-in-class AUM302, a PIM/PI3K/mTOR inhibitor being developed by AUM Biosciences. For more information, please visit

For further Information Contact:

Innoplexus AG

Claudia M. Hausoel, Marketing Management

T: +49 (0) 151 - 6198 7478

Inflection Biosciences Ltd

Darren Cunningham, Chief Executive Officer


T: +353 (0) 1 4003615


bottom of page